Brought to you by 
InterMune nets $144.4mm in notes offering
11 Feb 2002
Executive Summary
InterMune (pulmonary, infectious disease, and cancer therapeutics) netted $144.4mm (including the underwriters' overallotment) with a public offering of 5.75% convertible subordinated notes due 2006. The notes convert to common shares at $38.40 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
InterMune nets $144.4mm in notes offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice